$1.10
0[0.00%]
At close: May 2
$1.10
0[0.00%]
PreMarket: 4:00PM EDT
Allakos
(NASDAQ:ALLK)Latest News for Allakos Stock (NASDAQ:ALLK)
Allakos Stock (NASDAQ: ALLK)
Categories: All
Wednesday, May 01, 2024
Thursday, March 14, 2024
Wednesday, February 14, 2024
Wednesday, January 17, 2024
- JMP Securities Maintains Market Outperform on Allakos, Lowers Price Target to $3Benzinga Newsdesk - Jan 17, 2024, 2:16PM
- Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For WednesdayAvi Kapoor - Jan 17, 2024, 8:19AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Jan 17, 2024, 8:05AM
- Barclays Maintains Underweight on Allakos, Lowers Price Target to $1Benzinga Newsdesk - Jan 17, 2024, 6:17AM
- Jefferies Downgrades Allakos to Hold, Lowers Price Target to $1.5Benzinga Newsdesk - Jan 17, 2024, 5:56AM
Tuesday, January 16, 2024
- Gold Down 1%; PNC Financial Posts Upbeat EarningsAvi Kapoor - Jan 16, 2024, 2:14PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Jan 16, 2024, 12:31PM
- Crude Oil Edges Lower; Morgan Stanley Posts Upbeat RevenueAvi Kapoor - Jan 16, 2024, 11:53AM
- Allakos shares are trading lower after the company announced topline data from its phase 2 trial for lirentelimab in atopic dermatitis and its phase 2b study in chronic spontaneous urticaria did not meet their primary endpoints.Benzinga Newsdesk - Jan 16, 2024, 11:38AM
- Trial Setback: Allakos Drops Lead Skin Disorder Candidate, Cuts Workforce By 50%Vandana Singh - Jan 16, 2024, 10:33AM
- Dow Dips 200 Points; Goldman Sachs Earnings Top ViewsAvi Kapoor - Jan 16, 2024, 9:49AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Jan 16, 2024, 8:05AM
- Allakos Plans Not To Pursue Further Development Of Lirentelimab; Will Focus On AK006 Clinical Development And Additional Preclinical ProgramsBenzinga Newsdesk - Jan 16, 2024, 7:03AM
- Allakos Announced Topline Data From Its Phase 2 Trial For Lirentelimab In Atopic Dermatitis (ATLAS) And Phase 2B Study In Chronic Spontaneous Urticaria (MAVERICK); The Studies Did Not Meet Their Primary EndpointsBenzinga Newsdesk - Jan 16, 2024, 7:02AM
- Trading Halt: Halted at 6:55:31 a.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Jan 16, 2024, 6:55AM
Monday, December 18, 2023
Friday, December 08, 2023
Tuesday, November 28, 2023
Tuesday, November 14, 2023
Monday, November 13, 2023
Friday, October 13, 2023
Tuesday, October 03, 2023
Wednesday, September 27, 2023
- Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock UpsideVandana Singh - Sep 27, 2023, 2:50PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023Benzinga Insights - Sep 27, 2023, 11:00AM
- JMP Securities Initiates Coverage On Allakos with Market Outperform Rating, Announces Price Target of $11Benzinga Newsdesk - Sep 27, 2023, 5:09AM
Thursday, September 21, 2023
Tuesday, September 12, 2023
Monday, September 11, 2023
Thursday, September 07, 2023
Thursday, August 31, 2023
Tuesday, August 22, 2023
Monday, August 21, 2023
Wednesday, August 09, 2023
Monday, August 07, 2023
Friday, August 04, 2023
Wednesday, May 31, 2023
- Allakos Director Awarded $424K Worth of Stock OptionsBenzinga Insights - May 31, 2023, 11:03AM
- Director at Allakos Acquires Company Stock Options Worth 86,762 SharesBenzinga Insights - May 31, 2023, 11:03AM
- Allakos Board Member Awarded $424K Worth of Stock OptionsBenzinga Insights - May 31, 2023, 11:03AM
- Board Member at Allakos Acquires Company Stock Options Worth 86,762 SharesBenzinga Insights - May 31, 2023, 11:02AM